Table 3.
Univariate and multivariate analysis of factors associated with optimal adherence to TB Medications, ARV, and both (Dual) at 6 months
| TB Medication adherence N=104 (%)* |
ARV adherence N=70 (%)** |
Dual adherence N=68 (%)*** |
Dual Adherence Univariate OR (95% CI) |
Dual Adherence Multivariate OR (95%CI) |
||
|---|---|---|---|---|---|---|
| Gender | Male Female |
29/50 (58.0) 41/54 (75.9) |
25/31 (80.7) 35/39 (89.7) |
16/29 (55.2) 29/39 (74.4) |
1.00 (ref) 2.72 (0.99 – 7.44) |
1.00 (ref) 4.68 (1.11–19.68) |
| Age | <35 >=35 |
35/49 (71.4) 35/55 (63.6) |
24/28 (85.7) 36/42 (85.7) |
18/28 (64.3) 27/40 (67.5) |
1.00 (ref) 1.00 (0.37–2.71) |
2.95 (0.65 – 13.42) 1.00 (ref) |
| Completed Primary school | No Yes |
8/21 (38.1) 60/81 (74.1) |
10/16 (62.5) 48/52 (92.3) |
5/16 (31.3) 38/52 (73.1) |
1.00 (ref) 5.97 (1.76–20.26) |
1.00 (ref) 5.39 (1.03–28.25) |
| Previous MDR-TB Hx | No Yes |
24/44 (54.6) 46/60 (76.7) |
24/29 (82.8) 36/41 (87.8) |
16/29 (55.2) 29/41 (70.7) |
1.00 (ref) 1.96 (0.73–5.31) |
1.00 (ref) 0.78 (0.19–3.15) |
| Income(ZAR) | <R2010 >=R2010 |
32/48 (66.7) 32/48 (66.7) |
31/38 (81.6) 27/30 (90.0) |
23/38 (60.5) 20/30 (66.7) |
1.00 (ref) 1.30 (0.48–3.54) |
1.00 (ref) 1.96 (0.44–8.66) |
| Year Enrolled | 2011 2010 2009 |
38/42 (90.5) 28/42 (66.7) 4/20 (20.0) |
27/30 (90.0) 26/29 (89.7) 7/11 (63.6) |
26/30 (86.7) 18/29 (62.1) 1/11 (9.1) |
1.00 (ref) 0.25 (0.07–0.92) 0.02 (0.00–0.15) |
1.00 (ref) 0.41 (0.09–1.78) 0.01 (0.00–0.13) |
| Adverse Events on Treatment† | No Yes |
13/24 (54.2) 30/51 (58.8) |
11/15 (73.3) 28/33 (84.9) |
7/15 (46.7) 17/33 (51.5) |
1.00 (ref) 1.21 (0.36–4.12) |
*
Calculation based on individuals with adherence data (N=104) within the first 6 months follow-up
**
Calculation based on individuals with ARV adherence data (N=70) within the first 6 months follow-up
***
Analysis includes patients with ARV and TB adherence data (N=68)
†
Within the first 6 months of follow-up